Voloridge Investment Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-15,820
| Closed | -$6.63M | – | 1368 |
|
|
2025
Q3 | $6.63M | Sell |
15,820
-38,626
| -71% | -$13M | 0.02% | 664 |
|
|
2025
Q2 | $15.6M | Buy |
54,446
+5,961
| +12% | +$1.78M | 0.06% | 394 |
|
|
2025
Q1 | $14.9M | Buy |
48,485
+41,621
| +606% | +$14.3M | 0.06% | 437 |
|
|
2024
Q4 | $2.42M | Buy |
6,864
+2,221
| +48% | +$816K | 0.01% | 920 |
|
|
2024
Q3 | $1.66M | Buy |
+4,643
| New | +$1.57M | 0.01% | 962 |
|
|
2024
Q2 | – | Sell |
-13,263
| Closed | -$3.05M | – | 1373 |
|
|
2024
Q1 | $3.05M | Buy |
+13,263
| New | +$2.99M | 0.01% | 759 |
|
|
2023
Q4 | – | Sell |
-2,133
| Closed | -$482K | – | 1501 |
|
|
2023
Q3 | $482K | Buy |
+2,133
| New | +$491K | ﹤0.01% | 1216 |
|
|
2023
Q2 | – | Sell |
-4,478
| Closed | -$1M | – | 1585 |
|
|
2023
Q1 | $1M | Buy |
+4,478
| New | +$1.1M | 0.01% | 1126 |
|
|
2021
Q4 | – | Sell |
-24,953
| Closed | -$4.61M | – | 1862 |
|
|
2021
Q3 | $4.61M | Buy |
24,953
+17,268
| +225% | +$3.4M | 0.03% | 718 |
|
|
2021
Q2 | $1.38M | Buy |
+7,685
| New | +$1.46M | 0.01% | 1140 |
|
|
2020
Q4 | – | Sell |
-71,596
| Closed | -$7.23M | – | 1585 |
|
|
2020
Q3 | $7.23M | Buy |
71,596
+30,106
| +73% | +$3.3M | 0.06% | 336 |
|
|
2020
Q2 | $5.02M | Buy |
+41,490
| New | +$4.67M | 0.06% | 354 |
|
|
2020
Q1 | – | Sell |
-8,700
| Closed | -$766K | – | 1422 |
|
|
2019
Q4 | $766K | Sell |
8,700
-6,550
| -43% | -$576K | 0.01% | 718 |
|
|
2019
Q3 | $1.22M | Sell |
15,250
-20,184
| -57% | -$1.63M | 0.02% | 586 |
|
|
2019
Q2 | $2.77M | Buy |
+35,434
| New | +$3.31M | 0.08% | 264 |
|
|
2017
Q2 | – | Sell |
-6,426
| Closed | -$870K | – | 586 |
|
|
2017
Q1 | $870K | Buy |
+6,426
| New | +$973K | 0.02% | 399 |
|
|
2016
Q2 | – | Sell |
-3,904
| Closed | -$435K | – | 404 |
|
|
2016
Q1 | $435K | Buy |
+3,904
| New | +$494K | 0.01% | 278 |
|
|
2015
Q4 | – | Sell |
-25,909
| Closed | -$3.4M | – | 311 |
|
|
2015
Q3 | $3.4M | Buy |
25,909
+22,009
| +564% | +$3.53M | 0.16% | 137 |
|
|
2015
Q2 | $678K | Sell |
3,900
-9,041
| -70% | -$1.63M | 0.03% | 244 |
|
|
2015
Q1 | $2.23M | Buy |
+12,941
| New | +$1.97M | 0.11% | 176 |
|
|
2014
Q4 | – | Sell |
-6,300
| Closed | -$810K | – | 232 |
|
|
2014
Q3 | $810K | Buy |
+6,300
| New | +$649K | 0.04% | 88 |
|
|
2014
Q1 | – | Sell |
-3,109
| Closed | -$352K | – | 131 |
|
|
2013
Q4 | $352K | Buy |
+3,109
| New | +$280K | 0.07% | 89 |
|
Other funds holding UTHR
ACA
Voloridge Investment Management's UTHR Position: Q4 2025 in Review
Voloridge Investment Management sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 15,820 shares — an estimated $6.63M sold.
Voloridge Investment Management first reported a position in UTHR in Q4 2013 and held it in 22 quarters. The position peaked at $15.6M in Q2 2025. 838 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.
- Voloridge Investment Management reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
- Voloridge Investment Management sold 15,820 United Therapeutics shares in Q4 2025, an estimated $6.63M.
- Voloridge Investment Management first reported a position in United Therapeutics in Q4 2013 and held it in 22 quarters.
- Voloridge Investment Management's United Therapeutics position peaked at $15.6M in Q2 2025.
- 838 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.
Based on Voloridge Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.